Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 30

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 30
---

complete them at all or in a satisfactory or timely manner, which could delay or prevent us from obtaining regulatory approvals for,
or achieving market acceptance of, our product.

In addition, termination
of relationships with third parties may result in delays, inability to enter into arrangements with alternative third parties or do so
on commercially reasonable terms. Switching or adding additional clinical sites involves additional cost and requires management time
and focus. In addition, there is a natural transition period when a new clinical site commences work. As a result, delays occur, which
can materially impact our ability to meet our desired clinical development timelines.

<div align='center'>22</div>

We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.

Our ability to make scheduled
payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing
economic and competitive conditions and to financial, business, legislative, regulatory and other factors, some of which are beyond our
control. We cannot be sure that our business will generate sufficient cash flows from operating activities, or that future borrowings
will be available, to permit us to pay the principal, premium, if any, and interest on our indebtedness.

If our cash flows and capital
resources are insufficient to fund our debt service obligations, we could face substantial liquidity problems and could be forced to
reduce or delay investments and capital expenditures or to dispose of material assets or operations, seek additional debt or equity capital
or restructure or refinance our indebtedness. We may not be able to effect any such alternative measures, if necessary, on commercially
reasonable terms or at all and, even if successful, those alternative actions may not allow us to meet our scheduled debt service obligations.

Our inability to generate
sufficient cash flows to satisfy our debt obligations, or to refinance our indebtedness on commercially reasonable terms or at all, would
have a material adverse effect on our financial condition and results of operations. If we cannot make scheduled payments on our debt,
we will be in default, and the lenders under our credit facilities could terminate their commitments to loan money, the lenders could
foreclose against the assets securing their borrowings and we could be forced into bankruptcy or liquidation. Any of these events could
result in you losing all or a portion of your investment in our ordinary shares.

Our business, operating results and growth rates may